FDA Breakthrough Therapy Designation for NGN-401 Puts Neurogene at the Forefront of Rett Syndrome Innovation
Market Chameleon (Fri, 27-Feb 11:15 AM)
NGN-401 Granted FDA Breakthrough Therapy Status on Promising Rett Syndrome Trial Results
Market Chameleon (Fri, 27-Feb 7:06 AM)
